Ovation Fertility Licenses Genomic Prediction’s LifeView

Nashville, Oct. 21, 2022 (GLOBE NEWSWIRE) — Ovation^® Fertility has announced a new partnership with Genomic Prediction that will enhance and expand the genetic testing options available to hopeful parents. By licensing the company’s LifeView^TM PGT platform for use in Ovation Genetics labs, Ovation will be able to offer physicians and patients the most comprehensive preimplantation genetic testing (PGT) available to aid in the selection of optimal-quality embryos for transfer as part of IVF.

“At Ovation, our purpose is to bring the joy of parenthood through innovative science,” says Ovation Chief Executive Officer Paul Kappelman. “Every day, we strive to advance the state of the art in the science of IVF. This partnership with Genomic Prediction will ensure that our genetic testing capabilities stay a step ahead of the curve, helping us provide the best possible outcomes for people who come to us for help growing their families.”

Ovation Genetics helps create successful pregnancies by testing embryos for conditions that could lead to pregnancy loss, chromosomal disorders or genetic disease. PGT includes a range of genetic tests that optimize the selection of embryos for transfer, providing patients with the best chance of a healthy baby.

With five LifeView PGT options, Ovation will enhance and expand its PGT capabilities to provide even better outcomes for physicians and patients.  

• PGT-A (PGT for aneuploidy) is a comprehensive test for abnormal chromosome composition in an embryo. Studies comparing LifeView PGT to conventional NGS methods have demonstrated significantly improved clinical outcomes for IVF patients, including higher ongoing pregnancy rates and lower miscarriage rates. By combining copy number and genotyping data, LifeView provides the most accurate, highest-resolution prediction of chromosomal abnormalities available. Fewer false positives means more truly euploid embryos available for transfer.
• PGT-A+ (Aneuploidy…